Abstract
Background: Long non-coding RNAs (lncRNA) have been identified as novel molecular regulators in cancers. LncRNA ADAMTS9-AS2 can mediate the occurrence and development of cancer through various ways, such as regulating miRNAs, activating the classical signaling pathways in cancer, and so on, which have been studied by many scholars. In this review, we summarize the molecular mechanisms of ADAMTS9-AS2 in different human cancers.
Methods: Through a systematic search of PubMed, lncRNA ADAMTS9-AS2 mediated molecular mechanisms in cancer are summarized inductively.
Results: ADAMTS9-AS2 aberrantly expression in different cancers is closely related to cancer proliferation, invasion, migration, and inhibition of apoptosis. The involvement of ADAMTS9-AS2 in DNA methylation, mediating PI3K / Akt / mTOR signaling pathways, and regulating miRNAs and proteins, shows its significant potential as a therapeutic cancer target.
Conclusion: LncRNA ADAMTS9-AS2 can become a promising biomolecular marker and a therapeutic target for human cancer.
Keywords: Long non-coding RNA, ADAMTS9-AS2, malignant tumors, therapeutic targets, DNA methylation, mediating PI3K.
Current Pharmaceutical Design
Title:ADAMTS9-AS2: A Functional Long Non-coding RNA in Tumorigenesis
Volume: 27 Issue: 23
Author(s): Wen Xu, Bei Wang , Yuxuan Cai, Jinlan Chen, Xing Lv , Chong Guo and Chengfu Yuan*
Affiliation:
- College of Medical Science, China Three Gorges University, Yichang 443002,China
Keywords: Long non-coding RNA, ADAMTS9-AS2, malignant tumors, therapeutic targets, DNA methylation, mediating PI3K.
Abstract:
Background: Long non-coding RNAs (lncRNA) have been identified as novel molecular regulators in cancers. LncRNA ADAMTS9-AS2 can mediate the occurrence and development of cancer through various ways, such as regulating miRNAs, activating the classical signaling pathways in cancer, and so on, which have been studied by many scholars. In this review, we summarize the molecular mechanisms of ADAMTS9-AS2 in different human cancers.
Methods: Through a systematic search of PubMed, lncRNA ADAMTS9-AS2 mediated molecular mechanisms in cancer are summarized inductively.
Results: ADAMTS9-AS2 aberrantly expression in different cancers is closely related to cancer proliferation, invasion, migration, and inhibition of apoptosis. The involvement of ADAMTS9-AS2 in DNA methylation, mediating PI3K / Akt / mTOR signaling pathways, and regulating miRNAs and proteins, shows its significant potential as a therapeutic cancer target.
Conclusion: LncRNA ADAMTS9-AS2 can become a promising biomolecular marker and a therapeutic target for human cancer.
Export Options
About this article
Cite this article as:
Xu Wen , Wang Bei , Cai Yuxuan , Chen Jinlan , Lv Xing , Guo Chong and Yuan Chengfu *, ADAMTS9-AS2: A Functional Long Non-coding RNA in Tumorigenesis, Current Pharmaceutical Design 2021; 27 (23) . https://dx.doi.org/10.2174/1381612827666210325105106
DOI https://dx.doi.org/10.2174/1381612827666210325105106 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biological Activity In Vitro of Side-Chain Modified Analogues of Calcitriol
Current Pharmaceutical Design Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry Prospective Clinical Applications of CRF Peptide Antagonists
Current Molecular Pharmacology Large-Scale and Facile Synthesis of Biocompatible Yb-Based Nanoparticles as a Contrast Agent for In Vivo X-Ray Computed Tomography Imaging
Current Topics in Medicinal Chemistry The Potential for Targeting Oncogenic WNT/β -Catenin Signaling in Therapy
Current Drug Targets Recent Advances in the Design and Synthesis of Small Molecule Carbonic Anhydrase IX Inhibitors
Current Topics in Medicinal Chemistry Flavonoids as Sirtuin Modulators
Current Topics in Medicinal Chemistry The Role of Stress Proteins in Prostate Cancer
Current Genomics The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Current Pharmaceutical Design The Use of Technetium-99m Radiolabeled Human Antimicrobial Peptides for Infection Specific Imaging
Mini-Reviews in Medicinal Chemistry Physiology and Therapeutics of Vascular Endothelial Growth Factor in Tumor Immunosuppression
Current Molecular Medicine Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication
Current Drug Metabolism Choline Kinase Alpha Depletion Selectively Kills Tumoral Cells
Current Cancer Drug Targets Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy Small Molecule Kinase Inhibitors as Anti-Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry Phytocompounds from the Medicinal and Dietary Plants: Multi-target Agents for Cervical Cancer Prevention and Therapy
Current Medicinal Chemistry An Overview of Nano Delivery Systems for Targeting RNA Interference-based Therapy in Ulcerative Colitis
Current Pharmaceutical Design In silico Methods for Designing Antagonists to Anti-apoptotic Members of Bcl-2 Family Proteins
Mini-Reviews in Medicinal Chemistry Caveolin-1: A Promising Therapeutic Target for Diverse Diseases
Current Molecular Pharmacology VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets